Effect of Manuel Therapy on Tension Type Headache in Menopausal and Premenopasual Women (TTH-MT)

May 16, 2026 updated by: Ayça Seda, Necmettin Erbakan University

Comparison of the Effect of Manuel Therapy on Tension Type Headache in Menopausal and Premenopasual Women

This study aims to investigate the effectiveness of manual therapy in women with tension-type headache and to compare treatment outcomes between menopausal and premenopausal women. Hormonal changes occurring during menopause may influence pain perception and headache characteristics.

Participants diagnosed with tension-type headache will receive manual therapy interventions. Headache intensity, headache-related disability, pressure pain threshold, cervical range of motion, sleep quality, and quality of life will be evaluated before and after treatment using validated assessment tools. The results are expected to contribute to physiotherapy approaches in women experiencing tension-type headache during different hormonal periods.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Tension-type headache (TTH) is the most prevalent type of primary headache and is characterized by bilateral, pressing, or tightening pain of mild to moderate intensity. It has a considerable impact on daily activities, psychological status, sleep quality, and overall quality of life. Hormonal changes occurring during the menopausal transition may influence pain perception, musculoskeletal sensitivity, and headache characteristics. Therefore, investigating treatment responses in different hormonal periods may provide valuable clinical insights.

The aim of this study is to investigate and compare the effectiveness of manual therapy applications in menopausal and premenopausal women with tension-type headache. The study will include women diagnosed with tension-type headache who meet the inclusion criteria. Participants will be evaluated before and after the intervention period.

Manual therapy interventions including soft tissue techniques, cervical mobilization, and therapeutic exercises will be applied. Outcome measures will include headache intensity assessed with the Visual Analog Scale (VAS), headache-related disability evaluated using the Headache Impact Test (HIT-6), pressure pain threshold measured by algometer, cervical range of motion assessed using a goniometer, sleep quality evaluated with the Pittsburgh Sleep Quality Index (PSQI), and health-related quality of life measured with the Short Form-36 (SF-36).

The results of this study are expected to provide evidence regarding the role of manual therapy in the management of tension-type headache and contribute to physiotherapy practices targeting women in different hormonal stages.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ayça Seda Yıldırımer, PT, MSc
  • Phone Number: +90 507 409 08 99
  • Email: aycaseda29@gmail.com

Study Locations

    • Konya
      • Konya, Konya, Turkey (Türkiye), 42090
        • Recruiting
        • Necmettin Erbakan Univesity Faculty of Health Sciences
        • Contact:
        • Principal Investigator:
          • Neslihan Altuntaş Yılmaz, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Female participants aged between 45 and 65 years.
  • Diagnosis of tension-type headache.
  • Premenopausal or menopausal status.
  • HIT-6 score of 49 or higher.
  • Willingness to participate in the study.

Exclusion Criteria:

  • Use of hormone therapy.
  • History of cervical surgery.
  • History of neurological disease.
  • Pregnancy.
  • Inability to understand questionnaire forms.
  • Failure to attend treatment sessions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Premenopausal Women With Tension-Type Headache
Premenopausal women diagnosed with tension-type headache who will receive manual therapy interventions during the study.
Participants diagnosed with tension-type headache will receive manual therapy interventions including cervical mobilization, soft tissue techniques, and suboccipital muscle relaxation. Treatments will be applied by a physiotherapist during the study period.
Experimental: Menopausal Women With Tension-Type Headache
Menopausal women diagnosed with tension-type headache who will receive manual therapy interventions during the study.
Participants diagnosed with tension-type headache will receive manual therapy interventions including cervical mobilization, soft tissue techniques, and suboccipital muscle relaxation. Treatments will be applied by a physiotherapist during the study period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain İntensity (Visual Analog Scale - VAS)
Time Frame: Baseline and after 2 weeks of treatment
Pain intensity will be assesed using the Visual Analog Scale (VAS). Participants will rate their pain on a 10 cm horizontal line ranging from 0 (no pain) to 10 (worst imaginable pain)
Baseline and after 2 weeks of treatment
Headache İmpact (Headache İmpact Test - HİT-6)
Time Frame: Baseline and after 2 weeks of treatment
Headache-related disability will be evaluted using the Headache İmpact Test (HİT-6). This questionnaire assesses the impact of headaches on daily functioning, social activities and overall quality of life.
Baseline and after 2 weeks of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleep Quality (Pittsburgh Sleep Quality Index - PSQI)
Time Frame: Baseline and after 2 weeks of treatment
Sleep quality will be evaluated using the Pittsburgh Sleep Quality Index (PSQI), a self-reported questionnaire that assesses sleep quality and disturbances over the previous month. Higher scores indicate poorer sleep quality.
Baseline and after 2 weeks of treatment
Pressure Pain Threshold
Time Frame: Baseline and after 2 weeks of treatment
Pressure pain threshold will be measured using a digital algometer applied to the pericranial muscles. The minimum pressure that induces pain will be recorded.
Baseline and after 2 weeks of treatment
Cervical Range of Motion
Time Frame: Baseline and after 2 weeks of treatment
Cervical range of motion will be assessed using a universal goniometer to evaluate cervical flexion, extension, lateral flexion, and rotation movements.
Baseline and after 2 weeks of treatment
Executive Function (Trail Making Test Part B)
Time Frame: Baseline and after 2 weeks of treatment
Executive function and cognitive flexibility will be assessed using the Trail Making Test Part B (TMT-B). The test evaluates visual attention, processing speed, and task-switching ability. The time required to complete the test will be recorded.
Baseline and after 2 weeks of treatment
Depression Severity (Beck Depression Inventory)
Time Frame: Baseline and after 2 weeks of treatment
Depressive symptoms will be assessed using the Beck Depression Inventory (BDI), a 21-item self-report questionnaire designed to measure the severity of depressive symptoms.
Baseline and after 2 weeks of treatment
Quality of Life (SF-12)
Time Frame: Baseline and after 2 weeks of treatment
Health-related quality of life will be assessed using the SF-12 Short Form Health Survey. The SF-12 evaluates physical and mental components of health-related quality of life. Higher scores indicate better health-related quality of life.
Baseline and after 2 weeks of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Neslihan Altuntaş Yılmaz, PhD, Necmettin Erbakan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2025

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

May 1, 2026

Study Registration Dates

First Submitted

March 12, 2026

First Submitted That Met QC Criteria

March 12, 2026

First Posted (Actual)

March 17, 2026

Study Record Updates

Last Update Posted (Actual)

May 20, 2026

Last Update Submitted That Met QC Criteria

May 16, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

İndividual participant data collected during this study will not be publicly shared. The data will be used only for the purposes of this research and will be stored securely bu the research team.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tension Type Headache

Clinical Trials on Manuel Therapy

Subscribe